124 related articles for article (PubMed ID: 8276316)
1. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
2. Comparative clinical trial of regional anticoagulation for hemodialysis.
Akizawa T; Kitaoka T; Sato M; Koshikawa S; Hirasawa Y; Kazama M; Mimura N; Ota K
ASAIO Trans; 1988; 34(3):176-8. PubMed ID: 3058171
[TBL] [Abstract][Full Text] [Related]
3. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
[TBL] [Abstract][Full Text] [Related]
4. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
[TBL] [Abstract][Full Text] [Related]
5. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
[TBL] [Abstract][Full Text] [Related]
6. [The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].
Koshiyama Y; Kobori A; Ogihara M; Yokomoto Y; Ohtani K; Shimamura K; Iwaki M
Nihon Yakurigaku Zasshi; 1987 Dec; 90(6):313-20. PubMed ID: 3443413
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans.
Abe H; Tani T; Numa K; Endo Y; Yoshioka T; Kodama M
Artif Organs; 1992 Apr; 16(2):206-8. PubMed ID: 10078246
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
[TBL] [Abstract][Full Text] [Related]
9. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Akizawa T
Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
[TBL] [Abstract][Full Text] [Related]
10. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model.
Minamiguchi K; Kitazato KT; Nagase H; Sasaki E; Ohwada K; Kitazato K
Kidney Int; 2003 Apr; 63(4):1548-55. PubMed ID: 12631372
[TBL] [Abstract][Full Text] [Related]
11. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
[TBL] [Abstract][Full Text] [Related]
12. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
Hosokawa S; Oyamaguchi A; Yoshida O
ASAIO J; 1992; 38(1):59-60. PubMed ID: 1554918
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs.
Choi JH; Byun SY; Nam A; Han SM; Lee KP; Song KH; Youn HY; Seo KW
J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):122-129. PubMed ID: 29419934
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
16. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
[TBL] [Abstract][Full Text] [Related]
18. Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery.
Sato T; Tanaka K; Kondo C; Morimoto T; Yada I; Yuasa H; Kusagawa M; Deguchi K
ASAIO Trans; 1991; 37(3):M194-5. PubMed ID: 1751106
[TBL] [Abstract][Full Text] [Related]
19. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.
Park JH; Her C; Min HK; Kim DK; Park SH; Jang HJ
Int J Artif Organs; 2015 Nov; 38(11):595-9. PubMed ID: 26728787
[TBL] [Abstract][Full Text] [Related]
20. New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY).
Taenaka N; Shimada Y; Hirata T; Nishijima M; Yoshiya I
Crit Care Med; 1982 Nov; 10(11):773-5. PubMed ID: 6814824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
